Trial intelligence / Profile preview

PeriOlimel N4-E versus conventional fluid therapy in ERAS colorectal cancer surgery

2015-005325-39Phase 4Active

Sponsor: Dr. Antonio Arroyo SebastiÃ¡n
Start: May 2016
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Countries: 1

Overview

Phase 4, randomised, open-label trial of Peri-Olimel in colorectal cancer (CRC) (2 arms), sponsored by Dr. Antonio Arroyo SebastiÃ¡n. Primary endpoint: Surgical postoperative complications. Started May 2016; status: active.

Drugs

Peri-Olimel

Conditions

colorectal cancer (CRC)

Beyond the preview

Go deeper on 2015-005325-39.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2015-005325-39.